Upgrade to SI Premium - Free Trial

Goldman Sachs Upgrades Rocket Pharmaceuticals (RCKT) to Neutral

October 8, 2026 1:30 AM
Goldman Sachs analyst Richard Law upgraded Rocket Pharmaceuticals (NASDAQ: RCKT) from Sell to Neutral with a price target of $4.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Upgrades